Breast cancer medication risk

Cancer
Credit: Unsplash/CC0 Public Domain

New research led by Flinders University has found a link between beta-blockers and survival outcomes in some breast cancer patients.

Beta-blockers, commonly used to manage , were negatively associated with in patients with HER2 (Human Epidermal Growth Factor Receptor 2) positive advanced breast cancer, according to a new paper in the Frontiers In Oncology.

Using data collected from 2,777 patients in , the study showed worse survival outcomes for patients with HER2 positive ABC group using concomitant beta-blocker, compared to patients not using a BB.

"The research highlights a group of whose survival outcomes are profoundly poorer," says Professor of Clinical Pharmacology Michael Sorich, director of the Precision Medicine Group at Flinders University's College of Medicine and Public Health

"Given about 20% of breast cancer patients overexpress HER2—and cardiovascular toxicities are a known complication anti-HER2 therapies—this study importantly identifies a subgroup of patients in which we recommend further investigation to find strategies to improve treatment outcomes."

The research concluded: "Future research should aim to gain a deeper understanding of the effects of beta-blockers on specific breast cancer subtypes, cancer types, and cancer treatments."


Explore further

Indigenous American ancestry tied to HER2+ breast cancer

More information: Natansh D. Modi et al, The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data, Frontiers in Oncology (2020). DOI: 10.3389/fonc.2020.01130
Citation: Breast cancer medication risk (2020, September 29) retrieved 30 November 2020 from https://medicalxpress.com/news/2020-09-breast-cancer-medication.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments